Allergische Reaktionen auf COVID-19-Impfungen – Was HNO-Ärzte wissen sollten – Teil 1: Immunologische Grundlagen von Allergien auf Impfstoffe, Immunmechanismen von allergischen und pseudoallergischen Reaktionen; Teil 2: Charakteristika der mRNA-Impfstoffe BNT162b2- und mRNA-1273 zur Prophylaxe von COVID-19 und assoziierte Immunphänomene; Teil 3: Praktische Aspekte der Prophylaxe, Diagnostik und Therapie von Allergien auf COVID-19-Impfstoffe

Klimek, L.; Chaker, Adam; Cuevas, Mandy

doi:10.1055/a-1397-0754

Cited by 3 publications

(2 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Arguments against a causal relation are that a causal relation has not been reported and that SARS-CoV-2 vaccinations are usually well tolerated. However, there are a few reports about class 1–4 adverse advents after COVID-19 vaccination [ 1 , 2 ]. The most common adverse events in a study of 21,977 patients who received a vector-based vaccine in Russia were flu-like illness, injection site reactions, headache, and asthenia [ 1 ].…”

Section: Discussionmentioning

confidence: 99%

“…The most common adverse events in a study of 21,977 patients who received a vector-based vaccine in Russia were flu-like illness, injection site reactions, headache, and asthenia [ 1 ]. Adverse reactions to mRNA-based vaccines reported include allergetic reactions [ 2 ], supraclavicular lymphadenopathy (postvaccine adenopathy) [ 3 ], radiation recall phenomenon [ 4 ], or Bell's palsy [ 5 ]. According to the current literature, the risk for GBS after COVID-19 is higher than the risk after vaccination, similar to influenza [ 6 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Exacerbating Guillain–Barré Syndrome Eight Days after Vector-Based COVID-19 Vaccination

Finsterer

2021

Case Reports in Infectious Diseases

View full text Add to dashboard Cite

Since the introduction of mRNA technology-based and vector-based COVID-19 vaccines, adverse reactions to these agents have been occasionally reported. Exacerbation of Guillain–Barré syndrome (GBS) shortly after COVID-19 vaccination has not been communicated. The patient is a 32-year-old male who developed progressive sensory disturbances and muscle weakness 8 days after the first dosage of a vector-based vaccine. Cerebrospinal fluid investigations revealed a dissociation cyto-albuminque, and nerve conduction studies revealed demyelination. Intravenous immunoglobulin (IVIG) exhibited only a marginal effect for both sensory and motor deficits. The patient’s history was moreover positive for previous GBS with marked motor deficits 14 years earlier, which responded favourably to IVIG leading to almost complete recovery within 9 months of rehabilitation. Although apparently extremely rare, neurologists should remain vigilant for a potential recurrence of GBS after vaccination with a vector-based COVID-19 vaccine.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Exacerbating Guillain–Barré Syndrome Eight Days after Vector-Based COVID-19 Vaccination

Finsterer

2021

Case Reports in Infectious Diseases

View full text Add to dashboard Cite

show abstract

COVID-19-Impfungen: Replizierend oder Nichtreplizierend?

Klimek

Chaker

Cuevas

et al. 2021

Laryngorhinootologie

Self Cite

View full text Add to dashboard Cite

ZusammenfassungInnovative und wirksame Impfstrategien entwickeln sich zum wichtigsten Hebel zur Bekämpfung der durch SARS-COV-2 ausgelösten globalen Pandemie. Innerhalb weniger Monate wurden durch Wissenschaftler weltweit vielversprechende neue Vakzine entwickelt; hierbei nutzen mehrere Impfstoffe das Prinzip adenoviraler Vektoren zum Einbringen der eigentlich immunogenen Moleküle des SARS-Coronavirus zum Auslösen einer Immunantwort. Die vom russischen Gamaleya-Institut entwickelte COVID-19-Vakzine Sputnik V (Gam-COVID-Vac) nutzt die adenoviralen Vektoren 26 und 5, um das vollständige SARS-Spike-Protein zur Impfung einzubringen, wobei die unterschiedlichen adenoviralen Vektoren mögliche neutralisierende Effekte gegen Adenoviren umgehen und dadurch eine ausreichende Immunogenität auch bei der Zweitimpfung (booster) gewährleisten. Die bisher veröffentlichten Studien werden teils kontrovers diskutiert, u. a. wegen kleiner Fallzahlen in Phase II und früher klinischer Endpunkte in der Phase III. Auch die bisher fehlende Verfügbarkeit der vollständigen Studienprotokolle und Datensätze wurde in der wissenschaftlichen Gemeinschaft zur Kenntnis genommen. Vulnerable Patientengruppen könnten durch eine wie in Brasilien beschriebene erhaltene Vermehrungsfähigkeit der Ad5-Adenoviren oder wie in der Slowakei beobachtete fehlende Chargenreproduzierbarkeit gefährdet werden, ein Wirksamkeitsverlust der Impfung bei Gesunden ist möglich. Die finale Bewertung in einem geordneten Zulassungsverfahren (z. B. EMA) bleibt daher abzuwarten.

show abstract

COVID-19 mRNA Vaccination Mimicking Heart Attack in a Healthy 56-Year-Old Physician

Xinias

Mavroudi

Theodorou

et al. 2022

Infectious Disease Reports

View full text Add to dashboard Cite

We report our experience regarding a 56-year-old physician who developed severe symptoms mimicking a heart attack a few days after receiving the second dose of the new mRNA vaccine of Pfizer-BioNTech for COVID-19 protection. The patient is a healthy individual with no comorbidities and a normal clinical and laboratory profile. Five days after receiving the second dose on his left shoulder, he manifested sudden, severe pain on the whole left arm which lasted for about one hour, gradually intensifying and migrating to the chest and presenting as severe angina or heart attack. All work-up, however, was negative, with no evidence of ischemic heart attack or myocarditis. Severe acute symptoms lasted for about 20 h and completely resolved after 36 h. Although myocarditis as a potential side effect of the vaccine with associated heart pain has been identified, chest pain mimicking heart attack with otherwise normal workup has not been reported. Physicians must consider this likely rare and self-resolving symptom in order to increase awareness and prevent themselves and their patients from increased anxiety and unnecessary laboratory investigations.

show abstract

Cited by 3 publications

References 51 publications

Exacerbating Guillain–Barré Syndrome Eight Days after Vector-Based COVID-19 Vaccination

Exacerbating Guillain–Barré Syndrome Eight Days after Vector-Based COVID-19 Vaccination

COVID-19-Impfungen: Replizierend oder Nichtreplizierend?

COVID-19 mRNA Vaccination Mimicking Heart Attack in a Healthy 56-Year-Old Physician

Contact Info

Product

Resources

About